HomeCompareNTEC vs EPRT

NTEC vs EPRT: Dividend Comparison 2026

NTEC yields 20.77% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NTEC wins by $13.2K in total portfolio value
10 years
NTEC
NTEC
● Live price
20.77%
Share price
$9.63
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$76.5K
Annual income
$7,308.86
Full NTEC calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — NTEC vs EPRT

📍 NTEC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNTECEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NTEC + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NTEC pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NTEC
Annual income on $10K today (after 15% tax)
$1,765.32/yr
After 10yr DRIP, annual income (after tax)
$6,212.53/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $4,702.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NTEC + EPRT for your $10,000?

NTEC: 50%EPRT: 50%
100% EPRT50/50100% NTEC
Portfolio after 10yr
$70.0K
Annual income
$10,074.79/yr
Blended yield
14.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

NTEC
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NTEC buys
0
EPRT buys
0
No recent congressional trades found for NTEC or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNTECEPRT
Forward yield20.77%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$76.5K$63.4K
Annual income after 10y$7,308.86$12,840.73
Total dividends collected$44.4K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: NTEC vs EPRT ($10,000, DRIP)

YearNTEC PortfolioNTEC Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$12,777$2,076.84$11,205$505.18+$1.6KNTEC
2$16,151$2,479.95$12,672$682.46+$3.5KNTEC
3$20,212$2,929.82$14,490$930.48+$5.7KNTEC
4$25,053$3,426.51$16,786$1,282.69+$8.3KNTEC
5$30,776$3,969.42$19,753$1,791.56+$11.0KNTEC
6$37,488$4,557.19$23,677$2,541.64+$13.8KNTEC
7$45,300$5,187.86$29,008$3,672.99+$16.3KNTEC
8$54,329$5,858.83$36,463$5,425.08+$17.9KNTEC
9$64,699$6,567.01$47,238$8,221.57+$17.5KNTEC
10$76,537$7,308.86$63,385$12,840.73+$13.2KNTEC

NTEC vs EPRT: Complete Analysis 2026

NTECStock

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.

Full NTEC Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this NTEC vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NTEC vs SCHDNTEC vs JEPINTEC vs ONTEC vs KONTEC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.